Table 2 Primary analysis, baseline covariates after matching
From: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality
Matching Variable | Comparison Group (No TRTa) N = 210 | Treatment Group (TRTa) N = 165 | P-value | Standardized Mean Difference |
|---|---|---|---|---|
Median First Testosterone, ng/dL (IQR) | 173 (146, 198) | 179 (153, 203) | 0.397 | 0.265 |
Median Second Testosterone, ng/dL (IQR) | 170 (142, 198) | 172 (138, 193) | 0.798 | 0.085 |
Median Income, United States Dollars (IQR) | 54,468 (47,300, 69,769) | 59,311 (45,124, 70,631) | 0.612 | 0.440 |
Median Age, years (IQR) | 55 (49, 61.7) | 55 (49, 62) | 0.815 | 0.033 |
Diabetes (N, %) | 88 (41.9%) | 67 (40.6%) | 0.800 | 0.026 |
Tobacco Use (N, %) | 1 (0.5%) | 1 (0.6%) | 0.864 | 0.018 |
LDL > 130 mg/dL | 18 (8.6%) | 20 (12.2%) | 0.258 | 0.117 |
Median LDL, mg/dL (IQR) | 92 (73, 114) | 91 (68, 113) | 0.458 | 0.058 |
Hypertension (N, %) | 142 (67.6%) | 111 (67.3%) | 0.943 | 0.007 |
Statin (N, %) | 106 (50.5%) | 86 (52.1%) | 0.752 | 0.033 |
BMI ≥ 30 kg/m2 | 192 (91.9%) | 144 (87.3%) | 0.191 | 0.135 |
Median BMI, kg/m2 (IQR) | 36.3 (32.1, 40.8) | 35.6 (32.1, 40.1) | 0.290 | 0.291 |
Previous Cardiovascular Disease (N, %) | 36 (17.1%) | 33 (20.0%) | 0.478 | 0.074 |
Charlson Comorbidity Index (N, %) | 0.532 | 0.117 | ||
0 | 86 (41%) | 61 (37%) | ||
1 | 46 (21.9%) | 44 (26.7%) | ||
> 1 | 78 (37.1%) | 60 (36.3%) | ||
Composite Outcome (N, %) | 16 (7.6%) | 12 (7.3%) | ||
Myocardial Infarction (N, %) | 3 (1.4%) | 4 (2.4%) | ||
Stroke (N, %) | 10 (4.8%) | 6 (3.6%) | ||
Death (N, %) | 3 (1.4%) | 2 (1.2%) |